Betamethasone is a potent synthetic glucocorticoid (corticosteroid) with high anti-inflammatory, immunosuppressive, antipruritic, and vasoconstrictive properties. In the 0.1% w/w topical formulation, it is primarily used for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), which control the biosynthesis of potent mediators of inflammation like prostaglandins and leukotrienes.
Adult: Apply a thin film to the affected area 1 to 2 times daily. For most conditions, once-daily application is sufficient. Therapy should be limited to 2-4 weeks. For chronic conditions like psoriasis, intermittent therapy is recommended.
Note: Wash and dry the affected area gently. Apply a thin layer and rub in lightly until it disappears. Do not bandage or cover the area unless directed by a physician (occlusive dressing increases absorption and risk of side effects). Wash hands after application unless hands are the treatment site. Avoid contact with eyes, mouth, nose, and mucous membranes.
Betamethasone binds to specific intracellular glucocorticoid receptors. The activated receptor complex translocates to the cell nucleus, binds to glucocorticoid response elements (GREs) in DNA, and modulates gene transcription. This leads to the synthesis of anti-inflammatory proteins (lipocortins) and inhibition of genes encoding for pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α). It also inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Pregnancy: Pregnancy Category C (US FDA). Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies show teratogenicity. Use should be limited in amount and duration. Avoid high-potency steroids on large areas or under occlusion.
Driving: No effect on ability to drive or operate machinery.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects. | Major |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | May be used sequentially but concurrent use on same area not recommended; increased risk of infection. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | If systemically absorbed, metabolism of betamethasone may be reduced, increasing systemic exposure. | Moderate |
| Live Vaccines (e.g., BCG, MMR, Varicella) | Systemic immunosuppression from absorbed steroid may impair immune response and increase risk of vaccine-induced infection. | Major |
Same composition (Betamethasone (0.1% w/w)), different brands: